BioNTech is expanding the capacities for the production of the not yet approved COVID-19 vaccine. The Mainz-based biotech company is taking over a production facility for biotechnological substances in Marburg from Novartis. Novartis Pharma GmbH assumes that the sale signed yesterday can be completed this year. “The approval of the responsible authorities is still pending,” said the Novartis subsidiary.
No details are given about the financial details of the deal for the Marburg location.
“The employment relationships of all employees at the site will remain unaffected by the transaction. In the future, BioNTech plans to manufacture the COVID-19 vaccine candidate BNT162 in Marburg, ”said Novartis.
BioNTech is developing the vaccine in collaboration with Pfizer and – limited to China – with Fosun Pharma. In the USA, clinical development is on the home straight, and a study with 44,000 subjects is expected to be completed soon. BioNTech expects to be able to apply for approval for the COVID-19 vaccine BNT162 in late October or early November at the latest. Assuming the relevant data from the clinical tests, this should then be approved quickly. The plan is to produce 100 million doses of the vaccine by 2020, and more than a billion doses in 2021.
At a glance – chart and news: BioNTech